[COMPANY_001] Research and Development
LKA651
Clinical Trial Protocol CLKA651X2202
Study Registry ID: [REMOVED]
A randomized, active-c ontrolled, patient and investigator-
masked, multiple dose proof-o f-concept study of 
intravitreal LKA651 in patients with diabetic macular 
edema
Document type: Amended Protocol Version
EUDRACT number: 2018 -000031 -28
Version number: v06 (Clean )
Clinical Trial Phase: II
Release date: 06-Jul-2022
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
[COMPANY_001] Confidential Page 2
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details 
for study  procedures. Note: The SOM will not be a part of the Clinical Study Report.
[COMPANY_001] Confidential Page 3
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Table of contents
Site Operations Manual (SOM)........................................................................................... [ADDRESS_544303] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol summary .............................................................................................................. 21
1Introduction ....................................................................................................................... 24
1.1 Background ............................................................................................................ 24
1.1.1 Non Clinical Data .................................................................................. 24
1.1.2
Clinical Data.......................................................................................... 25
1.2 Purpose .................................................................................................................. 27
2Objectives and endpoints ................................................................................................... 27
3Study  design ................................ ................................ ................................ ...................... 28
4Rationale ............................................................................................................................ 30
4.1 Rationale for stud y design ..................................................................................... 30
4.2
Rationale for dose/regimen and duration of treatment .......................................... 31
4.3
Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 32
4.4 Purpose and timing of interim anal yses/design adaptations .................................. 32
4.5 Risks and benefits .................................................................................................. 32
4.5.1 Blood sample volume ............................................................................ 34
5Population ................................ ................................ ................................ .......................... 34
5.1 Inclusion criteria .................................................................................................... 34
5.2 Exclusion criteria ................................................................................................... 35
6Treatment ........................................................................................................................... 38
6.1 Study  treatment ...................................................................................................... 38
6.1.1 Investigational and control drugs .......................................................... 38
6.1.2 Additional study  treatments .................................................................. 38
6.1.3 Treatment arms/group ........................................................................... 38
Commercially Confidential Information (CCI)
[COMPANY_001] Confidential Page 4
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
6.2 Other treatment(s) ................................ ................................ ................................ ..39
6.2.1 Concomitant therap y ............................................................................. 39
6.2.2
Prohibited medication ........................................................................... 39
6.2.3
Rescue medication ................................................................................ 40
6.2.4 Restriction for study  patients ................................................................ 40
6.3 Patient numbering, treatment assignment, randomizatio n
..................................... 40
6.3.1
Patient numbering ................................................................................. 40
6.3.2 Treatment assignment, randomiza tion.................................................. 40
6.4 Treatment masking ................................................................................................ 40
6.4.1
Site staff ................................................................................................ 41
6.4.2 Sponsor staff .......................................................................................... 41
6.5
Dose escalation and dose modification.................................................................. 42
6.5.1 Dose escalation guidelines .................................................................... 42
6.6
Additional treatment guid ance............................................................................... 43
6.6.1 Treatment compliance ........................................................................... 43
6.6.2 Recommended treatment of adverse events .......................................... 43
6.6.3 Emergency  breaking of assigned treatment code .................................. 43
6.7 Preparation and dispensation ................................................................................. 44
7Informed consent procedures
............................................................................................ 44
8
Visit schedule and assessments ......................................................................................... 45
8.1 Screening ............................................................................................................... 48
8.1.1 Eligibility  Screening .............................................................................. 48
8.1.2 Information to be collected on screening failures ................................. 48
8.2 Patient demographics/other baseline characteristics ............................................. 48
8.3 Efficacy .................................................................................................................. 48
8.3.1 Efficacy  assessment 1 ........................................................................... 48
8.3.2 Efficacy  assessment 2 ........................................................................... 48
8.3.3 Appropriateness of efficacy  assessments .............................................. 49
8.4 Safety ..................................................................................................................... 49
8.4.1 Vital signs .............................................................................................. 49
8.4.2 Height and weight ................................................................................. 49
8.4.3 Laboratory  evaluations .......................................................................... 49
8.4.4 Electrocardiogram (ECG) ..................................................................... 50
8.4.5 Pregnancy  and assessments of fertility ................................................. 51
8.4.6 Other safety
 evaluations ........................................................................ 51
8.5
Additional assessments.......................................................................................... 53
[COMPANY_001] Confidential Page 5
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
8.5.[ADDRESS_544304] -study  treatment .......................................................... 57
10Safety  monitoring and reporting ................................ ................................ ........................ 58
10.1 Definition of adverse events and reporting requirements...................................... 58
10.1.1 Adverse events (AEs) ............................................................................ 58
10.1.2 Serious adverse events (SA Es)
.............................................................. 59
10.1.3 SAE reporting
........................................................................................ 60
10.1.4 Pregnancy  reporting .............................................................................. 61
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 61
10.2 Additional Safety  Monitoring ................................................................................ 62
11Data Collection and Database management ...................................................................... 62
11.1
Data collection....................................................................................................... 62
11.2 Database management and quality  control ................................ ............................ 62
11.3 Site monitoring ...................................................................................................... 63
12Data analy sis and statistical methods ................................................................................ 64
12.1 Analy sis sets .......................................................................................................... 64
12.2
Patient demographics and other baseline characteristics....................................... 64
12.3 Treatments ............................................................................................................. 64
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 65
12.4.1 Definition of primary  endpoint(s) ......................................................... 65
12.4.2 Statistical model, hy pothesis, and method of anal ysis
.......................... 65
12.4.3 Handling of missing values/censoring/discontinuations ....................... 65
12.4.4 Sensitivity  and Supportive anal yses...................................................... 65
12.5 Analy sis of secondary  endpoints ........................................................................... 66
Commercially Confidential Information
Commercially Confidential Information
CCI
[COMPANY_001] Confidential Page 6
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
12.5.2 Pharmacokinetics .................................................................................. 67
12.6 Analy sis of exploratory  endpoints ......................................................................... 68
12.7 Interim anal yses..................................................................................................... 68
12.8
Sample size calculation.......................................................................................... 69
13Ethical considerations and administrative procedures ...................................................... 70
13.1 Regulatory
 and ethical compliance ........................................................................ 70
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. [ADDRESS_544305] of tables
Table 2-1 Objectives and related endpoints ................................ .......................... 27
Table 6-1 Investigational drug ............................................................................... 38
Table 6
-2 Control Drug ......................................................................................... 38
Table 6
-3 Prohibited medication ........................................................................... 39
Table 6
-4 Masking levels ...................................................................................... 42
Table 8
-1 Assessment Schedule ............................................................................ 46
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... [ADDRESS_544306] of figures
Figure 3 -
1 Study  Design ................................ ................................ ......................... 30
Commercially Confidential Information
[COMPANY_001] Confidential Page 7
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
List of abbreviations
A1C Glycated haemog lobin
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
AUC 0-28d Area under the curve over the dosing interval
BCVA Best Corrected Visual Acuity
BMI Body Mass Index
BUN blood urea nitrogen
CBC Complete Blood Count
CDS Core Data Sheet (for marketed drugs)
CFP Color Fundus Photograp hy
CFR U.S. Code of Federal Regulation s
CI Confidence Interval
CK creatinine kinase
Cmax Maximum Concentration
CMO&PS Chief Medical Office & Patient Safety
CO 2 carbon dioxide
CRA Clinical Research Associate
CRC Central Reading Center
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
DAR Dose Administration Record
DDE Direct Data Entry
DME Diabetic Macular Edema
DNA Deoxyribonucleic Acid
DR Diabetic Retinopathy
e.g. For example
EC Ethics Committee
ECG Electrocardiogram
EDC Electronic Data Capture
EMA European Medicine Agency
EPO Erythropoietin
ETDRS Early Treatment Diabetic Retinopathy Study
eSource Electronic Source
FA Fluorescein Angiography
Fc Fragment cry stallizable 
FcRn Neonatal Fc receptor
FDA Food and Drug Administration
FIH First-in-Human
g/dL Grams/deciliter
GCP Good Clinical Practice
[COMPANY_001] Confidential Page 8
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
GLP Good Laboratory Practice
GGT Gamma -glutam yl transferase
h hour
Hb Hemoglobin
HbA1C Glycated haemoglobin
hCG Human chorionic gonadotropin
IV intravenous
IA Interim analysis
IB Investigators Brochure 
ICF Informed Consent Form
ICHInternational Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IND Investigational New Drug
IOP Intra Ocular Pressure
IRB Institutional Review Board
IRT Interactive Response Technology
IVT Intravitreal
LDH lactate dehydrogenase
LFT Liver function test
MedDRA Medical dictionary for regulatory activities
mg milligram (s)
mL milliliter(s)
NCDS [COMPANY_001] Clinical Data Standards
NOAEL No Observed Adverse Event Level
NOVDD [COMPANY_001] Data Dictionar y
NYHA [LOCATION_001] Heart Association
PCI percutaneous coronary intervention
PD pharmacodynamic(s)
PoC Proof of Concept
PK pharmacokinetic(s)
PRN Pro re nata; a s needed
Q4w Every 4 weeks
QMS Quality Management System
QTcF Fridericia QT corrected interval
RBC red blood cell(s)
RDC Remote Data Capture
SAE serious adverse event
sCR serum creatinine
SD standard deviation
SD-OCT Spectral domain optical coherence tomography
Commercially Confidential Information
[COMPANY_001] Confidential Page 9
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
SMQ Standardized MedDRA Query
SOM Site Operations Manual
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
Tmax Time to the first occurrence of the maximal concentration
TD Study Treatment Discontinuation
US [LOCATION_002]
VEGF Vascular Endothelial Growth Factor
WBC white blood cell(s)
WHO World Health Organization
WoC Withdrawal of Consent
[COMPANY_001] Confidential Page 10
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A specific group of patient s fulfilling certain criteria
Control drug Any drug(s) (an active drug or an inactive drug, such as a placebo) which is 
used as a comparator to the investigational drug being tested in the trial
Dosage Dose of the study treatment given to the patient in a time unit (e.g. 100 mg 
once a day, 5 mg once a month )
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is t he electronic acquisition of clinical study 
data using data collection systems, such as Web-based applications, 
interactive voice response sy stems and clinical laboratory interfaces. 
EDC includes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcribed from paper source forms used at the point of 
care.
Enrollment Point/time of patient entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Epoch Interval of time in the planned conduct of a study. An epoch is associated with 
a purpose (e.g. screening, randomization, treatment, follow -up) which applies 
across all arms of a study.
eSource eSource Direct Data Entry (DDE) refers to the capture of clinical study data 
electronically, at the point of care. eSource combines source documents and 
case report forms (eCRFs) into one application, allowing for the real time 
collection of clinical trial information to sponsors and other oversight 
authorities , as appropriate.
Investigational 
drugThe study drug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synony mous with “investigational new drug,” "Investigational Medicinal 
Product," or “test substance”
Part A single component of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a single 
dose part and a multiple dose part, or a part in patients with established 
disease and in those with newly -diagnosed disease.
Patient An individual with the condition of interest
Personal data Subject information collected by [CONTACT_221963]. This data includes subject identifier 
information, study information and biological samples.
Randomization 
numberA unique identifier assigned to each randomized patient , corresponding to a 
specific treatment arm assignment
Screen Failure A patient who is screened but is not treated or randomized
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource
Study treatment Any drug or combination of drugs administered to the study participants as 
part of the required study procedures; includes investigational drug(s), 
control(s) or background therapy
Study treatment 
discontinuationWhenthe patient permanently stops taking study treatment prior to the defined 
study treatment completion date
Patient A trial participant (can be a healthy volunteer or a patient)
[COMPANY_001] Confidential Page 11
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Patient number A unique number assigned to each patient upon signing the info rmed consent. 
This number is the definitive, unique identifier for the patient and should be 
used to identify the patient throughout the study for all data collected, sample 
labels, etc.
Personal Data Personal Data: Subject information collected by [CONTACT_351966]. This data includes 
subject identifier information, study information and biological samples .
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study
Withdrawal of 
consent (W oC)Withdrawal of study consent: Withdrawal of consent from the study occurs 
only when a subject does not want to participate in the study any lon ger, and 
does not allow any further collection of personal data
[COMPANY_001] Confidential Page 12
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 13
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 14
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 15
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 16
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 17
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 18
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 19
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 20
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Commercially Confidential Information
[COMPANY_001] Confidential Page 21
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Protocol summary
Protocol number CLKA651X2202
Full Title A randomized, active -controlled, patient and investigator -masked, multiple 
dose proof -of-concept study of intravitreal LKA651 in patients with diabetic 
macular edema 
Brief title A proof -of concept study  of intravitreal LKA651 in patients with macular edema
Sponsor and 
Clinical Phase[COMPANY_001]
Phase II
Investigation type Biologic
Study type Interventional
Purpose and 
rationaleThis study  will investigate whether LKA651, alone or when co-administered 
with Lucentis®, displays the clinical safety and efficacy  profile to support 
further development to treat diabetic macular edema (DME)
Primary 
Objective(s) To evaluate the safety ,tolerability, and efficacy , in reference to Lucentis®
monotherapy, of three q4w intravitreal (IVT)doses of LKA651 in treating DME
when administered as monotherapy and in combination with Lucentis®.
Secondary 
ObjectivesTo evaluate the serum pharmacokinetic (PK) profile of total LKA651 and 
Lucentis ®following three q4w IVT doses of LKA651 ,or a combination of 
LKA651 and Lucentis ,®in patients with DME
To evaluate duration of effect of three q4w IVT doses of LKA651 in patients 
with DME .
Study design This study is a 3-arm, parallel group, randomized, patient and investigator -
masked trial in [ADDRESS_544307] the safety of the 
combination of LKA651 and Lucentis®before proceeding with further patient 
randomization . After determination of safety from Day 15 data from each 
sentinel cohort, patients will continue to be enrolled into 1 of 3 arms; LKA651 
monotherapy, LKA651 plus Lucentis®, and Lucentis®monotherapy.  Every 
patient will be dosed 3 times in4 week intervals , and then followed for an 
extension phase of an additional 12 weeks during which PRN Lucentis®may 
be given.  
Population Approximately [ADDRESS_544308] 75 patient s are expected to complete the 
study.
[COMPANY_001] Confidential Page 22
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Key Inclusion 
criteriaMale and female patients age 18 to 85years of age inclusive at
screening
Diagnosis of ty pe I or type II diabetes mellitus.
The Early Treatment Diabetic Retinopathy Study ( ETDRS )letter score in
the study eye must be between 24 and 72letters (approximate Snellen
equivalent of 20/40 -20/320). The non -study  eye (fellow eye) should be
≥34 letters or better (approximate Snellen equivalent of 20/200) at
screening
Presence of DME in the study eye , with decrease in vision due to foveal
thickening . Central macular thickness of≥ 320µmin the central subfield,
as assessed on spectral -domain ocular coherence tomography (SD-
OCT )and confirmed by [CONTACT_430332] E xclusion 
criteria
Study treatment LKA651
Lucentis®(ranibizumab)
Efficacy 
assessmentsBest corrected visual acuity (BCVA)
Central subfield retinal thickness as determined by [CONTACT_66309] -OCT
Pharmacokinetic 
assessmentsSerum levels of total LKA651
Serum levels of total ranibizumab
Commercially Confidential Information
[COMPANY_001] Confidential Page 23
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Key safety 
assessmentsOcular or systemic adverse events
Vital signs
Electrocardiogram (ECG)
Safety laboratories (including reticulocyte count)
Intraocular pressure
BCVA
Central subfield retinal thickness by  [CONTACT_66309]-OCT
Other 
assessments 
Data analysis The primary  objective of this study is to assess the safety  and tolerability as 
well as the efficacy  of LKA651 alone or in combination with Lucentis®in 
patients with DME. Descriptive statistics will be provided for all safety 
variables. Adverse events will be summarized by [CONTACT_124141], rates and body  
system.  For efficacy  evaluation, BCVA and central subfield retinal thickness 
at week 12 are the primary endpoints. A repeated measure Analy sis of 
Covariance (ANCOVA) will be performed for BCVA and change from baseline 
BCVA. Independent variables will include treatment, visit, and the treatment 
by [CONTACT_23259]. Baseline BCVA will be used as a covariate. Central subfield 
retinal thickness will be analy zed in a similar fashion as BCVA, except that 
central subfield retinal thickness will be log-transformed, thus results will be 
back -transformed in order to show results as a ratio to baseline and the 
difference between treatments will be expressed as a ratio of treatments.
Key words Diabetic Macular Edema (DME)
Commercially Confidential Information
[COMPANY_001] Confidential Page 24
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
1 Introduction
1.1 Background
Diabetic retinopath y (DR) is the most common visual complication in patients with diabetes. 
Diabetic macular edema (DME) can occur in any stage of DR and is the main cause of vision 
loss in patients with DR. The incidence of DME after 10 years of follow -up has been reported 
to be 20.1% in Type 1 Diabetes Mellitus, 25.4% in Type 2 insulin -dependent diabetes, and 13.9% 
in Type 2 non- insulin -dependent diabetes (Klein et al1995). The early treatment diabetic 
retinopathy  (ETDRS) 
trial, a pi[INVESTIGATOR_430318], demonstrated that although laser 
photocoagulation therapy  reduces the risk of moderate visual loss in DME eyes by ~50% at 
3years (ETDRS 1985), only a few eyes gain vision, and some eyes continue to experience 
vision loss even after intensive treatment (ETDRS 1985). Newer treatment options such as anti-
vascular endothelial growth factor ( VEGF )therapy  have helped, but even in these pi[INVESTIGATOR_430319] y 50% of eyes are left with visual acuities of 20/40 or worse (Mitchell et
al2011).
LKA651, an anti -erythropoietin (EPO) Fab (antibody fragment), may be an effective treatment 
for patients with DME. In DME patients, intraocular EPO concentrations are elevated in eyes 
with DME (for example Lim and Han, 2011)
. 
The most relevant data for the present study are summar ized in the sections below. For detailed 
information, please refer to the Investigator's Brochure (IB).
1.1.1 Non Clinical Data
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 25
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
1.1.2 Clinical Data
[IP_ADDRESS] Human Safety  and Tolerability  Data
Safety  and tolerability  data from thefirst-in-human (FIH) trial CLKA651X2104 showed that 
all doses were safe and well tolerated. This study was a single-ascending dose study  with 
28 patients who had macular edema from DME, retinal vein occlusion, or neovascular age-
related macular degeneration.  
Analyses conducted and detailed in the IBrevealed no deaths, discontinuations, or serious 
adverse events (SAEs) among randomized patients. Eighteen patients had [ADDRESS_544309] common AE
related to the procedure was conjunctival hemorrhage, occurring in 4(16.7%) patients. 
Two AEs : anterior chamber inflammation in one patient in 
Commercially Confidential Information
Commercially Confidential Information
CCI
[COMPANY_001] Confidential Page 26
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
 resolved within 24 hours oftreatment with topi[INVESTIGATOR_28709], and trace vitreous cell in one patient seen within 
two weeks of injection of drug , that resolved without treatment, and then recurred at the end of 
study  (Day  85). There were no AEs related to red blood cell production or anemia. There were 
no non- ocular AEs that were related to the stud y drug. 
[IP_ADDRESS] Human pharmacokinetic s, pharmacody namics and immunogenicity
data
Commercially Confidential Information
CCI
Commercially Confidential Information
[COMPANY_001] Confidential Page 27
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
1.2 Purpose
This study  is being conducted to evaluate the safety /tolerability and efficacy  of IVT LKA651 
for the treatment of macular edema in patients with DME.
2 Objectives and endpoints
Table 2-1 Objectives and rel ated endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
To evaluate the safety/tolerability of 
three q4w IVT doses of LKA651 alone 
or in combination with Lucentis®in 
patients with DME .Ocular and systemic AEs
Vital signs (blood pressure, heart rate) and ECG 
intervals.
Safety laboratory measures (including reticulocyte 
count)
Complete ophthalmic exam, including :
Intraocular Pressure (IOP)
BCVA
Macular thickness by  [CONTACT_375038] ( SD-OCT) 
FA
To evaluate the efficacy , in reference 
to Lucentis®monotherapy, of three 
q4w IVT doses of LKA651 in treating 
DME when administered as 
monotherapy or in combination with 
Lucentis®.Best Corrected Visual Acuity (BCVA) as assessed 
by [CONTACT_63365] (Early Treatment Diabetic Retinopathy 
Study) visual acuity charts at week 12.
Central subfield retinal thickness as measured by 
[CONTACT_66309]-OCT at week 12.
[COMPANY_001] Confidential Page 28
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Objective(s) Endpoint(s)
Secondary objective(s) Endpoint(s) for secondary objective(s)
To evaluate duration of effect of three
q4w IVT doses of LKA651 in patients
with DME.Time to retreatment with anti -VEGF (as
determined by [CONTACT_976]) after week 12 during a n
additional 12-week extension phase
To evaluate the serum
pharmacokinetic profile of total
LKA651 and Lucentis®following three
q4w IVT doses of LKA651 alone or in
combination with Lucentis®in patients
with DME .Serum levels of total LKA651 ( Maximum
concentration ( Cmax )and Area under the curve
(AUC )0-28din monotherapy or in combination with
Lucentis®after the first dose in a subset of patients
with sufficient quantifiable serum samples to permit
meaningful analysis.
Serum levels of ranibizumab (Cmax and AUC 0-28d)
when administered in combination with LKA651
after the first dose in a sub set of patients with
sufficient quantifiable serum samples to permit
meaningful analysis.
Exploratory objective(s) Endpoint(s) for exploratory objective(s)
[ADDRESS_544310] that clinically  tests the 
combination of  LKA651 and Lucentis®, therefore the study  will be stratified in that 
Sentinel Safety  cohorts will first be enrolled to test the safety  of a patient receiving both 
LKA 651 and Lucentis®as separate injections in the same eye before proceeding with further 
patient enrollment (See Section 4.5). Because the study  will be run both in and ex-U.S., different 
doses of Lucentis®will be used in each region per label. Ex-U.S.
, the Sentinel Safety  cohort 
will use the maximum dose of Lucentis®globall y (0.5mg). In the U.S., the approved dose for 
DME is 0.3 mgso this dose will be used. Foreach Sentinel Safety  cohort, 8 patients will be 
randomized 6:1:1 to L KA651+Lucentis®(  + 0.3 mg or 0.5 mg), LKA651 monotherap y 
( ), and Lucentis®monotherap y (0.3 or 0.5 mg). When two injections are required, as in 
the combination arm, the injections will be given 30 minutes apart. To maintain masking in the 
Commercially Confidential Information
CCI
CCI
CCI
[COMPANY_001] Confidential Page 29
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
monotherap y arms, a sham injection will be given as a second injection [ADDRESS_544311] drug injection (Asham injection is a needle -less syringe placed against the globe with 
pressure simulating that of an injection) . Safet yassessments through Day 15 will be analy zed 
for all8 patients before any other patients from the same geograph ical region can be randomized ; 
in the FIH study , the two AEs considered related to the study  drug occurred within this time 
frame.
Within each geographical region, masked analy sis of Day  15 safet y data of the Sentinel Safet y 
cohort will be performed by a joint review by [CONTACT_430333]. Data review will include the nature of adverse events, vital signs, 
electrocardiogram, safety  laboratories (including reticulocy te count, intraocular pressure, 
BCVA, , slit lamp examination), and central subfield retinal thickness by 
[CONTACT_66309]-OCT.
After determination that there are no concerning safet y signals, the study  will proceed with 
randomization for the remaining 74 patients who will be randomized 9:14: 14 to LKA651
+Lucentis®(  + 0.3 or 0.5 mg), LKA651 monotherap y ( ), or Lucentis®monotherap y 
(0.3 or 0.5 mg). Masking with sham injections will be performed as in the safety  sentinel cohorts. 
Data from the Safet y Sentinel cohorts and main study  will be pooled for end-of-study  safety 
and efficacy  anal ysis.  
For all patients, a screening period of 60 days will be used to assess eligibility  and to taper 
patient s off disallowed medications. At Visit 1, the baseline visit, eligible patient s will be 
randomized to one of the treatment arms. Randomized patient s will be dosed once q4weeks for 
a total of 3 doses. The assessment to address the primary objective will be performed at the end 
of the treatment period (week 12) before the extension phase begins. After 
12 weeks, efficacy 
will be determined based on BCVA criteria. Patients are then followed for an additional 
12weeks in a maintenance/extension phase for further evaluation of secondary  endpoints. 
During the extension phase, patients will be examined every  4weeks and receive PRN anti-
VEGF treatment (Lucentis®) as determined by [CONTACT_430334] y significant increase 
in retinal thickness or decrease in BCVA due to DME that warrants anti -VEGF treatment. 
CCI
CCI
CCI
[COMPANY_001] Confidential Page 30
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Figure 3-1 Study  Design
In each region, Sentinel Safety cohort is randomized 6:1:1 Combination: LKA651: Lucentis®.Main study 
is randomized 9:14:14
4 Rationale
4.1 Rationale for study  design
The design of this study  addresses the primary  objective of improvement of BCVA in patients 
with DME and takes into account the possible additive effects of LKA651 with anti-VEGF 
treatment.
Sentinel safety cohorts: The combination of LK A651 
 and rani bizumab 0.5 mg 
was shown to be safe in a multiple dose, 13- week GL P toxicology  study  (see IB).  
Limiting the initial clinical exposure of the combination of LKA651+Lucentis®to 
6patient s in the U.S. and 6 patient s outside the U.S., controls the risk associated with 
potential adverse events that may  occur with this combination that has not yet been tested 
in humans, but has been shown safe in preclinical toxicity  studies. Including one patient 
treated with LKA651 and one patient treated with L ucentis®monot herap y in the 
Sentinel Safety  cohort allows for comparison and control. In addition, because the rest of 
the patient population will be screened onl y after Day  15 of the Sentinel Safet y cohorts, 
the 
Sentinel Safety  cohorts will remain ahead of the other pa tients for the duration of the 
study , and will provide alerts to potential AEs occurring after multiple doses. 
Lucentis®alone is an approved treatment for DME, and LKA651 has shown an acceptable 
safet y profile in the FIHstudy  CLKA651X2104, so overall the risk for unanticipated 
SAEs is considered to be very  low. Performing the Sentinel Safet y cohort both within and 
Ex-U.S. will allow the study to begin in the U.S., where the approved dose for Lucentis®
for DME is lower bu t where the stud y ma y begin more quickly  due to operational reasons.
CCI
[COMPANY_001] Confidential Page 31
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Randomization: This decreases the chance of an imbalance in patient characteristics
between groups, thereb y facilitating an unbiased assessment of safet y and tolerability .
Patient -masked (with selective un -masking of investigators and sponsor staff for
operational or safety reasons): Masking of patient s and investigators allows for an
unbiased assessment of readouts such as adverse events. Selective un -masking of the
investigators and spon sor staff could improve the accuracy  of safety -related decisions
ifnecessary .
4.2 Rationale for dose/regimen and duration of treatment
Two separate doses of LKA651 will be used in this study ,  in the monotherapy  arm and 
 in combination with Lucent is®in the combination arm. 
Because there are noavailable animal models of DME, the dose/response relationship is 
unknown for LKA651 alone or incombination with Lucentis®. Thus it is propose dto test the 
highest safe and tolerable dose of LKA651 as determined by [CONTACT_209446]-in-human study 
CLKA651X2104  in the monotherapy  armof thisproof -of-concept study . Injection of 
the maximum deliverable single dose of LKA651  in the monotherapy  arm is supported 
by
[CONTACT_430335]651 and Lucentis®could
lead to superior efficacy  in thecombination arm compared to the monotherapy  arm; therefore 
a combination arm will be tested. T he combination (two separate injections given 30 minutes 
apart)   of  LKA651 and Lucentis®at the approved dose for DME is supported by [CONTACT_941] 
13week intravitreal LKA651/ ranibizumab combination toxicology  study in cynomolgus 
monkey s. For the combination arm with ranibizumab, the proposal is to evaluate the same 
dose of LKA651 used in the 13-week IVT LKA651/ranibizumab toxicology study  (  
LKA651) and the same or lower dose of ranibizumab used (0.5 mg ranibizumab outside the 
U.S.and 0.3 mg used within the U.S. per label). 
Dosing every four weeks is an approved dosing frequency for Lucentis®in treating DME and 
will be employ ed in this study . Since macular edema in diseases such as DME isslowly  
progressive, several months of treatment and observation are required to detect any potential 
clinical efficacy with LKA651 as a monotherapy  or in free combination with Lucentis®. 
Theproposed length of treatment, 12 weeks ,is supported by [CONTACT_203327] 13-week 
GLP-toxicology  study, and is consistent with a timeframe by [CONTACT_9444] a clinically significant 
change in DME can be expected. 
CCI
CCI
CCI
CCI
Commercially Confidential Information
CCI
CCI
[COMPANY_001] Confidential Page 32
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
Luce ntis®will be used both as a monotherapy  comparator and in combination with LKA651 
for safet y and efficacy  measurements. Anti -VEGF therapy  is standard of care for patients with 
DME, and Lucentis®has a well established safet y and efficacy  profile with approved use per 
label atdoses of 0.3 mg monthly  within the U.S. and 0.5 mg monthly  outside the U.S.  
Using Lucentis®as a monotherapy  comparator will help establish if any safety  or tolerabilit y 
effects of LKA651 areattributed to the study  drug as opposed to an effect of study  procedures 
such as intraocular injection. I n addition, because LKA651 has a different mechanism of action 
than anti-VEGF therapy , the combination of the two may provide additional efficacy  benefits 
not seen with either alone. 
4.4 Purpose and timing of interim analy ses/design adaptations
4.5 Risks and benefits
LKA651 is an anti -EPO antibody  that may  be effective in treating DME (sy mptoms or signs), 
either alone and/or in combination with anti-VEGF therapy . Because the mechanism of 
LKA651 differs from anti-VEGF standard of care, treatment with LKA651 may offer improved 
or additional benefits to both patients who respond to anti -VEGF treatment, and those who do 
not.
Commercially Confidential Information
[COMPANY_001] Confidential Page 33
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
The risk to patient s in this trial may be minimized by [CONTACT_5345], as well as close clinical monitor ing. Potential human safet y concerns 
include intraocular inflammation. 
 Further support is tendered by  [CONTACT_430336] , in whi ch one case of anterior chamber inflammation was seen after one injection of 
 LKA651, and one case of trace vitreal cells was reported 2 weeks after injection of 
LKA651 ( Section [IP_ADDRESS] ). Investigators should carefull y monitor patients' ey es during the 
assessments immediately  after study  drug administration, and any adverse event should be 
treated according to type and local practice. Other risks not specific to LKA651 include 
hypersensitivity  reactions, or si de effects from intraocular injection including endophthalmitis. 
Refer to the IB for more information.
This study  is the first to clinically  test the combination of  LKA651 and Lucentis®.
Thelow risk to patients is supported by [CONTACT_17978] -compliant 13-week IVT study  which found 
the combination of  LKA651 and 0.5 mg ranibizumab safe and well tolerated. 
Combining another ocular drug with Lucentis®has been shown to be safe in trials investiga ting 
other compounds
.  These include intravitreall y-administered anti-platelet derived growth factor
aptamer (Jaffe et al2016), a complement factor C5 inhibitor (Mone s 2010 ), and a topi[INVESTIGATOR_430320], squalamine ( Wroblewski andHu2016). Furthermore, LKA651  was safe and well 
tolerated in the FIH study  CLKA651X2104. In addition, the Sentinel Safety  cohorts will 
mitigate risk by [CONTACT_430337] a few patients whose safety  data will 
be closel y monitored, and further randomization will be gated b y the review of these data after 
Day 15.
Some patients in the trial will be assigned to LKA651 without concomitant anti-VEGF therapy . 
Appropriate eligibility criteria regarding vision and concomitant retinal disease
, rescue criteria, 
and stoppi[INVESTIGATOR_430321] y.Rescue medication may be given per Section 6.2.3. Furthermore, the study  period is 
only 3
 months of duration, with an extension phase of an additional 3 months during which 
patients may  receive PRN L ucentis®treatment.
Sodium Fluorescein: Fluorescein angiograph y is considered a relatively  safe procedure, 
although numerous adverse reactions have been reported in the literature. These are divided 
into mild (nausea, vomiting, pruritus, sneezing, vaso-vagal disorders, inadvertent arterial 
injection), moderate (urticaria, other skin eruptions, syncope, thrombophlebitis, pyrexia, local 
tissue necrosis, muscular paral ysis) and severe (bronchospasm, laryngeal edema, circulatory 
shock, m yocardial infarction, tonic -clonic seizure). In a randomized trial, out of 1,500 enrolled 
patients, 69.3% underwent the test for the first time. Nausea occurred in 71 (6.83%) patients, 
vomiting in 14 (1.35%), urticaria in 11 (1.06%), bronchospasm in 4 (0.38%) and laryngeal 
edema in 1 (0.01%). Higher incidences of adverse reactions were observed i n diabetic patients 
[p<0.002, RR=1.80 (CI=1.24- 2.60)], patients with systemic arterial hypertension [p<0.002, 
RR=1.84 (CI=1.26- 2.71)] and patients with allergy history  [p<0.001, RR=3.90 (CI=2.70
-5.63)]. 
A cumulative incidence of 9.72% adverse reactions was observed in patients who had 
undergone this test for the first time ( Liraet al 2007).
Commercially Confidential Information
CCI
CCI
CCI
CCI
CCI
CCI
[COMPANY_001] Confidential Page 34
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
4.5.1 Blood sample volume
A volume smaller than a typi[INVESTIGATOR_297175] a period of 
6months from each patient as part of the study . The maxim um drawn at any given day is 
approximately 31 mL. Additional samples may  be required for safet y monitoring.
Timings of blood sample collection are outlined in the Assessment Schedule .
A summary  blood log is provided in the Site Operations Manual (SOM). Instructions for all 
sample collection, processing, 
storage and shipment information is also available in the SOM 
and central laboratory  manual.
[ADDRESS_544312] been treated
with anti- VEGF therap y>[ADDRESS_544313] (e.g. checklist) of the eligibility  criteria must be stored with the source 
documentation at the study  site.
Deviation from any entry  criterion excludes a patient from enrollment into the study .
5.[ADDRESS_544314] meet allof the following criteria:
1.Written informed consent must be obtained before any assessment is performed .
2.Male and female patients age [ADDRESS_544315] be between 24 and 72 letters ,inclusive
(approximate Snellen equivalent of 20/40 -20/320). The non -study  eye (fellow ey e) should
be ≥34 letters or better ( approximate Snellen equivalent of 20/200) at screening
6.Sufficiently  clear ocular media and adequate pupil dilation in the study  eyeto permit
fundus photographs of adequate clarity  to measure diameters of retinal arteries and veins
at screening
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 35
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
7.At screening vital signs (sy stolic and diastolic blood pressure and pulse rate) will be
assessed in the sitting position after the patient has rested for at least three minutes.
TheInvestigator should be guided by  [CONTACT_430338] :
Bodytemperature between 35.0-37.5 °C
systolic blood pressure, 90 -180 mm Hg
diastolic blood pressure, 50
-100 mm Hg
pulse rate, 40 - 100 bpm
8. Able to communicate well with the investigator, to understa nd and comply with the
requirements of the study
5.2 Exclusion criteria
Patient s meeting an y of the following criteria are not eligible for inclusion in this study .
1.Patient with history  of treatment for DME in the study eye as defined by [CONTACT_716]:
IVTanti-VEGF treatment in the study  eye.  
History  or concurrent treatment with these medications/procedures in the non-
study  eye is permitted .
Patient with history  of intraocular corticosteroids in the study  eye including
dexamethasone intravitreal implants during the 6 month period prior to
baseline, 
2.Concomitant conditions or ocular disorders in the study  eye which m ay, in the opi[INVESTIGATOR_70340], confound the interpretation of study  results, compromise visual
acuity  or require medical or surgical intervention during the study  period
High risk proliferative diabetic retinopath y in the study  eye, as per invest igator
assessment at both screening and baseline.
Patients with the following conditions in the study  eye at screening or baseline
must be excluded: , vitreous hemorrhage, retinal
detachment, vitreomacular traction, macular hole, retinal vein/arterial occlusion,
neovascularization of iris or choroidal neovascularization of any  cause.
3.Laser photocoagulation (macular ) in the study  eye 
4.Patients, with ty pe [ADDRESS_544316] a hemoglobin A1C ≥ 12% at
screening.
5.Any progressive disease of the retina (e.g. uveitis, rod- cone dystrophy ) or optic nerve
in the study  eye.
6. Area of retinal ischemia involving the macula (as measured b y the foveal avascular
zone) ≥ 1000 μm in linear diameter .
7.Active intraocular inflammation (graded as trace or above) in either ey eat screening .
8.Any active infection involving the stud y eye’s ocular adnexa including infectious
conjunctivitis, keratitis, scleritis, endophthalmitis, as well as idiopathic or
autoimmune -associated uveitis in either ey e, or intraocular infection in either ey e.
CCI
Commercially Confidential Information
CCI
CCI
CCI
[COMPANY_001] Confidential Page 36
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
14.Current diagnosis of clinically  significant anemia, orhemoglobin < 10 g/dL for women
and < 11 g/dL for men.
22. Use of other investigational drugs at the time of enrollment, or within 5 half- lives of
enrollment, whichever is longer; or longer if required by  [CONTACT_427].
23.Pregnant or nursing (lactating ) women, where pregnancy  is defined as the state of a
female after conception and until the termination of gestation, confirmed b y a positive
hCG laboratory  test.
24.Women of childbearing potential, defined as all women phy siologicall y capable of
becoming pr egnant, unless they are using highly  effective methods of contraception
during duration of the study . Highl y effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the
patient). Periodic ab stinence (e.g. calendar, ovulation, sy mptothermal, post- ovulation
methods) and withdrawal are not acceptable methods of contraception.
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 37
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks before taking 
investigational drug. In case of oophorectom y alone, only when the reproductive status 
of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening ). For female patients on the 
study  the vasectomized male partner should be the sole partner for that patient.
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS) or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception .
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_5311] a minimu m of 3 months before taking investigational drug.
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history  of vasomotor sy mptoms) or have had surgical 
bilateral oophorectomy  (with or without hy sterectomy ), total h ysterectom y or tubal 
ligation at least six weeks ago. In the case of oophorectom y alone, onl y when the 
reproductive status of the woman has been confirme d by [CONTACT_430339].
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible patients.
[COMPANY_001] Confidential Page 38
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
[ADDRESS_544317] udy treatment
The investigational drug is LKA651  either alone or in free combination with Lucentis®
0.3mg (U.S. sites) or 0.5 mg (ex-U.S. sites). Lucentis®(0.3 or 0.5 mg) will also be given in a 
control arm as monotherapy .
Detailed information regarding the materials/medications supplied to the study  clinic(s) can be 
found in the SOM and pharmacy  manual.
6.1.1 Investigational and control drugs
The investigational drug, LKA651 20 mg/0.2 ml (Table 6-1) will be provided by [CONTACT_430340].
Lucentis®(0.3 or 0.5 mg) is used as active control arm in a monotherap y and in combination 
with 
Table 6-1 Investigational drug
Investigational
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
AdministrationSponsor 
(global or 
local)
LKA651 20 
mg/0.2m lLiquid in Vial IntravitrealOpen label 
bulk supply[COMPANY_001]
LKA651 (vehicle) NA NAOpen label 
bulk supply[COMPANY_001]
Lucentis ®10 
mg/ml solution for 
injection
(used in the 
combination arm)Liquid in Vial IntravitrealMarketed 
drugN/A
Table 6-2 Control Drug
Control Drug
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
AdministrationSponsor 
(global or 
local)
Lucentis®10 mg/ml
solution for injectionLiquid in Vial IntravitrealMarketed 
drugN/A
6.1.2 Additional study treatments
No additional treatment bey ond investigational drug and control drug are included in this trial.
6.1.3 Treatment arms/group
For each Sentinel Safety cohort, 8 patients will be assigned at visit 1 to one of the following 
3treatment arms/groups in a ratio of 6:1:1: LKA651 + Lucentis®free combination : LKA651: 
Commercially Confidential Information
CCI
[COMPANY_001] Confidential Page 39
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Lucentis®. The remaining 74 patients will be randomized 9:14:14 : LKA 651 + Lucentis®free 
combination: L KA651: Lucentis®.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
If the fellow ey e has DME it may  be treated with local (intravitreal or topi[INVESTIGATOR_2855]) medications per 
the investigators discretion. The fellow ey e may  be treated at any time, including on the stud y 
day, provided its treatment does not interfere with the timing of the study  procedures and 
assessments. 
The investigator must instruct the patient to notify the study  site about any new medications 
he/she takes after enrollment into the study . 
All prescription medications, over-the-counter drugs and significant non-drug therapi[INVESTIGATOR_014] 
(including ph ysical therapy  and blood transfusions) administered or taken within the timeframe 
defined in the entr y criteria prior to the start of the study  and during the study, must be recorded 
on the Concomitant medications/Significant non -drug therapi[INVESTIGATOR_50061].
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_232119] a patient 
or, if the patient is already  enrolled, to determine if the patient should continue participation in 
the study .
6.2.2 Prohibited medication
Use of the tre atments display ed in the below Table 6 -3are not allowed .
Table 6-3 Prohibited medication
Medication Prohibition period Action taken
Ozurdex®implantProhibited in the study eye at any time 
<6 m onths before or during the studyNote protocol 
deviation
Iluvien®implantProhibited in the study eye at any time 
before or during the studyNote protocol 
deviation
Investigational drugsAtDay 1 or any time th e patient is still 
enrolled in the trial.Discontinue from 
study treatment
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 40
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
6.2.[ADDRESS_544318].  In the case that clinically  significant deterioration in a patient’s 
vision or progression of macular edema occurs as determined by [CONTACT_430341], 
laser photocoagulation can be administered in an attempt to rescue the patient’s vision if rescue 
treatment is needed within [ADDRESS_544319] treatment injection, the patient can be treated as needed with Lucentis®for any further 
required rescue therapy . After any rescue treatment, the patient should discontinue the 
experimental treatment.  However, unless the investigator feels it is not in the best interest of 
the patient o r their condition, all patients who receive rescue medication should still participate 
in the scheduled visits and assess
ments as outlined in the study Assessment Schedule . 
Use of rescue medication/treatment must be recorded on the Concomitant 
medications/Significant non- drug therapi[INVESTIGATOR_430322].
6.2.4 Restriction for study  patient s
Not applicable .
6.3 Patient numbering, treatment assignment, randomization
6.3.1 Patient numbering
The patient number assigned to apatient at screening remains the unique identifier for the 
patient throughout the study . For information on patient numbering, please see 
‘
Patient numbering’ section in the Site Operations Manual.
6.3.[ADDRESS_544320] numbers to randomization numbers.  These randomization 
numbers are linked to the different treatment arms .
6.4 Treatment masking
Patients, investigator staff, persons performing the assessments, and data analy sts willremain 
masked to the identity  of study  treatments according to the specifications provided in the SOM. 
Randomization data are kept strictly  confidential until the time of unmasking for the respective 
person(s). Further information regarding masking (and unmasking) is presented in Table 6-4
and the SOM.
Patients will be randomized to a treatment arm to maintain the mask. Patients will remain 
masked to study  treatment throughout the study , except where indicated below. 
The identity  of the treatments will be concealed by [CONTACT_50090], labeling, schedule of administration, appearance, and odor.
[COMPANY_001] Confidential Page 41
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
6.4.1 Site staff
With the exception of any unmasked site staff identified below, all site staff (including study 
investigator and stud y nurse) will be masked to study treatment during treatment allocation and 
patient dosing. 
Unmasking a single patient at site for safet y reasons (necessary  for patient management) will 
occur via an emergency  system in place at the site (see Section 6.6.3) 
Drug product will be supplied in bulk, so an unmasked pharmacist or study  coordinator who is 
independent of the study  team will be required in order to maintain the masking. This unmasked 
pharmacist or study  coordinator will randomize the patient in the IRT system . Appropriate 
measures must be taken by [CONTACT_430342]. The injecting physician, 
different from the investigator performing the assessments, will also be unmasked.
Theinjecting physician will perform the injection and all assessments at [ADDRESS_544321] dose. Either 
the unmasked (injecting) or masked physician may perform the 
dilated fundus examination on the day of injection (2-[ADDRESS_544322] injection). All other 
assessments will be completed by  [CONTACT_286823].
6.4.2 Sponsor staff
The following unmasked sponsor roles are required for this study :
Unmasked field monitor(s)
Unmasked clinical staff managing drug re -supply to site
Unmasked sample anal yst(s) (PK blood and urine)
The unmasked field monitors are required to review drug accountability  and allocation at site. 
The unmasked monitors are not provided with a randomization list directly but will be 
unmasked through review of source documentation compi[INVESTIGATOR_430323], 
which details treatment allocation to individual patients. The unmasked monitors will also be 
able to review the treatment allocation cards/randomization list provided to the unmasked 
pharmacist. The names of the unmasked monitor(s) are detailed in the Monitoring Plan.
Sponsor clinical staff are required to assist in the management and re -supply  of investigational 
drug product. These individuals are not provided with randomization lists directly , but may  be 
unmasked through communication of drug re -supply  needs via the unmasked site pharmacists. 
The sample analysts will receive a copy of the randomization schedule (via request to the 
Randomization Office), to facilitate analy sis of the samples. The sample analy sts will provide 
the sample data to the study  team under unmasked conditions unless otherwise allowed. 
The study  statistician will be able to access the full randomization list from the start of the study 
and is allowed to share unmasked information with the rest of the clinical trial team as 
appropriate for internal decision purposes, as outlined in Table 6-4. For example, unmasked 
summaries and unmasked individual data can be shared with the tea
m whenever necessary . 
Study  programmers and other personnel involved in study  data anal ysis
 are allowed to access treatment assignment 
information from the start of the study  for the purpose of data anal ysis. 
CCI
[COMPANY_001] Confidential Page 42
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
The clinical trial team is allowed to share unmasked results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the study or the project while 
the study  is ongoing.
All unmasked personnel will otherwise keep randomization lists and data or information that 
could unmask other study team members confidential and secure except as described above. 
Following final database lock all role s may  be considered unmasked.
Table 6-[ADDRESS_544323] generatedTreatment 
allocation & 
dosingSafety event 
(single patient
unmask ed) 
dose 
escalation
Patient s/Patients M M UI M
Site staff M M UI UI
Unmasked site staff (see text for 
details) M UI UI UI
Drug Supply and Randomization 
OfficeUI UI UI UI
Unmasked sponsor staff (see text for 
details)UI UI UI UI
Unmasked Pharmacovigilance 
sponsor staffUI UI UI UI
Statistician/statistical 
programmer/data analystsM M UI UI
Independent committees used for 
assessing interim resultsNA NA NA NA
All other sponsor staff not identified 
above (trial team, project team, 
management & decision boards, 
support functions)M M UI UI
MRemains masked
NA Not applicable
UI Allowed to be un masked on individual patient level
6.5 Dose escalation and dose modification
Study  drug dose adjustments and/or interruptions are not permitted.
In case of notable adverse events or safet y concerns, termination of any further doses may be 
considered as per Section 9.
These changes must be recorded on the Dosage Administration Record CRF.
6.5.1 Dose escalation guidelines
Not applicable .
CCI
[COMPANY_001] Confidential Page 43
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
6.6 Additional treatment guidance
6.6.1 Treatment compliance
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all patient s 
treated with LKA651 and L ucentis®, as detailed in pharmacokinetics section.
6.6.2 Recomme nded treatment of adverse events
Ocular adverse events should be treated according to the type of adverse event. For clinically 
significant acute elevation of IOP following LKA651, anterior chamber paracentesis should be 
performed and normalization of IOP verified. For subacute or persistent elevation in IOP, 
aqueous suppressants may be indicated. 
Iritis or vitritis should be treated with steroidal or non-steroidal anti-inflammatory  medications; 
other medications such as cy cloplegics may  be indicated; endo phthalmitis should be ruled out.
Endophthalmitis should be treated with vitreous tap and culture and/or vitrectomy , as indicated, 
plus appropriate IVT antibiotics.
In case of an adverse event attributed to LKA651, such as clinically  significant inflammatio n 
or signs of retinal toxicity  not responsive to standard of care treatment, the investigator may 
wish to remove the LKA651 by  [CONTACT_430343] .
Systemic h ypersensitivity reactions are theoretically possible. These can manifest with itching, 
flushing, headache, nausea /vomiting, hypotension, urticaria, bronchospasm, or angioedema. 
Assess and treat for anaphy laxis if indicated, and in itiate supportive care. Fluids, vasopressors, 
corticosteroids, antihistamines, bronchodilators, and oxy gen should be on hand.
Patients shou ld remain in the study  even after receiving treatments for adverse events until the 
PI [INVESTIGATOR_430324].
Medication used to treat AEs must be recorded on the Concomitant medications/Significant 
non-drug therapi[INVESTIGATOR_50061].
6.6.[ADDRESS_544324] often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficien t to treat a study  patient who presents with an emergency 
condition. Details will be provided in the SOM.
Commercially Confidential Information
[COMPANY_001] Confidential Page 44
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
The unmasked treatment code should not be recorded on the eCRF.
It is the investigator’s responsibility  to ensure that there is a procedure in place to allow access 
to IRT (Interactive Response Technology ) or code break cards in case of emergency . 
Ifappropriate, the investigator will inform the patient how to contact [CONTACT_5657]/her backup in cases of 
emergency  when he/she is unavailable.
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs section.
LKA651 and Lucentis®will be administered to the patient via intraocular injection at the study 
site. When administered in combination, they will be given as separate injections 30minutes 
apart. If a patient is randomized to a monotherapy  arm, a sham injection will be done [ADDRESS_544325] injection. See the SOM for further details.
Sponsor qualified medical per sonnel will be readily  available to advise on trial related medical 
questions or problems.
7 Informed consent procedures
Eligible patient s may  only  be included in the study  after providing (witnessed, where required 
by [CONTACT_6617]), Institutional Review Board/I ndependent Ethics Committee (IRB/IEC )-
approved informed consent.
If applicable, in cases where the patient 's representative(s) gives consent (if allowed according 
to local requirements), the patient must be informed about the study  to the extent possible given 
his/her understanding. If the patient is capable of doing so, he/she must indicate agreement by 
[CONTACT_37249] y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific p rocedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the patient source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the International Conference on Harmonization (ICH ) Good Clinical 
Practice (GCP ) guidelines and regulatory  requirements and is considered appropriate for this 
study . Any changes to the proposed consent form suggested b y the investigator m ust be agreed 
by [CONTACT_111908] I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the IB and/CDS for marketed drugs . This information will be included in the patient
informed consent and should be discussed with the patient during the study  as needed. Anynew 
information regarding the safet y profile of the investigational drug that is identified between IB 
updates will be communicated as appropriate, for example, via an investigato r notification or 
an aggregate safet y finding. New information might require an update to the informed consent 
and then must be discussed with the patient .
[COMPANY_001] Confidential Page 45
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknow n risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
Male patient s must be informed that if a female partner becomes pregnant while he is en rolled 
in the study , contact [CONTACT_49414].
A copy of the approved version of all consent forms must be provided to [COMPANY_001]/sponsor after 
IRB/IEC approval.
Refer to the S OMfor a complete list of I CFs included in this study .
8 Visit schedule and assessments
Assessment Schedule lists all of the assessments and indicates with an “X”, the visits when they 
are performed. All data obtai ned from these assessments must be supported in the patient’s 
source documentation.
Patients should be seen for all visits/assessments as outlined in the Assessment Schedule or as 
close to the designated day/time as possible. Missed or rescheduled visits should not lead to 
automatic discontinuation. Patients who prematurely  discontinue the study  for any reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed 
for the final visit will be performed. At this final visit, all dispensed investigational product 
should be reconciled, and the adverse event and concomitant medications recorded on the CRF.
Commercially Confidential Information
[COMPANY_001] Confidential Page 46
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Table 8-1 Assessment Schedule
Epoch Screening Baseline Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment Follow -up Follow -up Follow -up Study Completion2
Visit Name [CONTACT_159337] 1 Visit 1 2Visit 12Visit 4 –
Telephone 
visitVisit 5 Visit 5 2Visit 52Visit 6 –
Telephone 
VisitVisit 7 Visit 7 2Visit 72Visit 8 Visit 9 Visit 10 Visit 11
Visit Numbers110 1010 1010 1010 1040 1050 1050 1050 1060 1070 1070 1070 1080 1090 1100 1999
DaysScreen
-60 to -11 1 1 15 29 29 29 43 57 57 57 85 113 141 169
Visit Window (Days) +/- 1 +/- 1 +/- 2 +/- 3 +/- 3 +/- 3 +/- 3 +/- 3
Inclusion / Exclusion 
criteriaX X
Hem atology3X X X X X X
Clinical Chemistry X X X X X
Pulse rate X X X X X X X X
Dem ography X
Physical 
ExaminationX X
Body Height X
Body Weight X X X X X
Study completion 
informationX
Concomitant 
therapi[INVESTIGATOR_21055] X X X X X X X X X
Blood Pressure X X X X X X X X
Informed consent X
Body Temperature X X X X X X X X
Adverse Events X X X X X X X X X X X X X
ECG evaluation X X X
Urinalysis X X X X
Medical 
history/current 
medical conditionsX X
Ocular history X
DME history X
Pregnancy and 
assessments of 
fertilityX4X4X4X4X4
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 47
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Epoch Screening Baseline Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment Treatment Follow -up Follow -up Follow -up Study Completion2
Visit Name [CONTACT_159337] 1 Visit 1 2Visit 12Visit 4 –
Telephone 
visitVisit 5 Visit 5 2Visit 52Visit 6 –
Telephone 
VisitVisit 7 Visit 7 2Visit 72Visit 8 Visit 9 Visit 10 Visit 11
Visit Numbers110 1010 1010 1010 1040 1050 1050 1050 1060 1070 1070 1070 1080 1090 1100 1999
DaysScreen
-60 to -11 1 1 15 29 29 29 43 57 57 57 85 113 141 169
Visit Window (Days) +/- 1 +/- 1 +/- 2 +/- 3 +/- 3 +/- 3 +/- 3 +/- [ADDRESS_544326] corrected 
visual acuity (BCVA)X X X6X X6X X6X X X X
Intraocular Pressure 
(IOP)X X X X X X X X X X X
Slit lamp 
biom icroscopyX X X X X X X X X X X
Dilated fundus exam X X X7X X7X X7X X X X
Optical coherence 
tomography8 X X X X X X X X
Fluorescein 
angiographyXXX
Color fundus photo X X X X X
HbA1C X X X
PK blood collection X5X5X5X5X
Study drug 
administrationX X X
1Visit structure given for internal programming purpose only
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 48
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
8.1 Screening
8.1.1 Eligibility S creening
Rescreening is onl y allowed b y permission of the Sponsor. 
In the case where a safety  laboratory  assessment at screening and/or initial baseline is outside 
of the range specified in the exclusion criteria, the assessment may be repeated once prior to 
randomization. If the repeat value remains outside of the specified ranges, the patient must be 
excluded from the study .
Information on what data must be collected for screening failures and further information on 
re-screening is outlined in the Site Operations Manual.
8.1.2 Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatmen t for an y reason will be 
considered a screen failure. The reason for not being started on treatment will be entered on the 
screening phase disposition page. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for screen failure patients. No other data will 
be entered into the clinical database for patients who are screen failures, unless the patient 
experienced a SAE during the screening phase (see SAE section for reporting details). 
8.2 Patient demographics/othe r baseline characteristics
Patient demographic and baseline characteristic data as outlined in the SOM will be collected 
on all patients.
Relevant medical history /current medical conditions data includes data until signature [CONTACT_86220].
8.3 Efficacy
8.3.1 Efficacy  assessment 1
[IP_ADDRESS] Best -Corrected Visual A cuity  (BCV A)
ETDRS BCVA will be obtained in each eye separatel y. This assessment is to be performed 
prior to pupil dilation. The number of letters read correctly  (for each eye) will be recorded in 
the appropriate eCRF page.
8.3.2 Efficacy  assessment 2
[IP_ADDRESS] Spectral -Domain Optical coherence tomography  (SD-OCT)
SD-OCT will be performed on the designated eye(s) for each patient according to the 
Assessment Schedule (Table 8-1) and the imaging manual provided by [CONTACT_430344] (CRC). SD -OCT images will be transferred to the CRC. Certification of the
 equipment 
and examiners at each investigative site will occur prior to evaluation of study  patients.
[COMPANY_001] Confidential Page 49
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
8.3.[ADDRESS_544327] s correlate (DRCRnet 2007), and thus BCVA will 
be the primary  efficacy  readout. 
8.4 Safet y
Safety  assessments are specified below; methods for assessment and reco rding are specified in 
the SOM, with the Assessment schedule (Section
8) detailing when each assessment is to be 
performed.
8.4.1
Vital signs
Body temperature
Blood pressure (BP)
Pulse 
8.4.2 Height and weight
Height
Body weight
Body mass index (BMI) will be calculated as (Body  weight (kg) / [Height (m)]2)
8.4.3 Laboratory  evaluations
In the case where a laboratory  assessment that is listed in the inclusion/exclusion criteria is 
outside of a protocol -specified range at screening and/or at the initial baseline , the assessment 
may be repeated once prior to randomization. If the repeat value remains outside of 
protocol -specified ranges, the patient is excluded from the study .
In the case where a laboratory  range is not specified by [CONTACT_760], but is outside the reference 
range for the laboratory  at screening and/or initial baseline , a decision regarding whether the 
result is of clinical significance or not shall be made by  [CONTACT_430345], in 
part, upon the nature and degree of the observed abnormality . The assessment may be repeated 
once prior to randomization.
In all cases, the Investigator must document in the source documents, the clinical considerations 
(i.e., result was/was not clinically  significant and/or medicall y releva nt) in allowing or 
disallowing the patient to continue in the study .
Clinically  relevant deviations of laboratory test results occurring during or at completion of the 
study  must be reported and discussed with [COMPANY_001] personnel. This includes laboratory 
evaluations obtained at Baseline visit V1, if the results are not received until after study  drug 
has been administered .  The results should be evaluated for criteria defining an adverse event 
and reported as such if the criteria are met. Repeated evaluatio ns are mandatory  until 
normalization of the result(s) or until the change is no longer clinically  relevant. In case of doubt, 
[COMPANY_001] personnel should again be contact[INVESTIGATOR_530].
[COMPANY_001] Confidential Page 50
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
[IP_ADDRESS] Hematology
CBC (Hemoglobin, hematocrit, red blood cell count, white blood count, platelet count) white 
blood cell differential (e.g. neutrophils, basophils, eosinophils, monocy tes, lymphocy tes) and 
reticulocy te count will be measured.
Additional measurements of hemoglobin A1c, CBC, and reticulocy tes will be measured as 
outlined in the Assessment Schedules . Sample handling will be as outlined in the laboratory 
manual. 
[IP_ADDRESS] Clinical chemistry
Albumin, alkaline phosphatase, total bilirubin, bicarbonate/CO 2, calcium, cholesterol, chloride, 
creatinine, creatinine kinase (CK) , gamma -glutamyl transferase (g-GT), glucose, lactate 
dehy drogenase (LDH), inorganic phosphorus, lipase, amylase, magnesium, potassium, total 
protein, aspartate aminotransferase (AST), alanine aminotransferase (ALT), sodium, 
triglycerides, urea/ blood urea nitrogen (BUN) and uric acid will be measured.
If the total bilirubin concentration is increased above 1.[ADDRESS_544328] reacting bilirubin should be differentiated.
Sample handling will be outl ined in the laboratory manual.
[IP_ADDRESS] Urinaly sis
A midstream urine sample (approximately  30 mL) will be obtained, in order to avoid 
contamination with epi[INVESTIGATOR_107183], and allow proper assessments.
A semi -quantitative "dipstick" evaluation for the following parameters will be performed: 
specific gravity , pH, glucose, protein, bilirubin, ketones, nitrite, leukocy tes and blood.
If the dipstick result is positive for protein, nitrite, leucocy tes and/or blood, the sample will be 
sent for microscopic ana lysis of white blood cells (WBC), red blood cells (RBC) and casts.
8.4.4 Electrocardiogram (ECG)
The Fridericia QT correction formula (QTcF) should be used for clinical decisions.
Single [ADDRESS_544329] be discussed with the spon sor.
Clinically  significant abnormalities should be recorded on the relevant section of the medical 
history /Current medical conditions/AE CRF / e(CRF) page as appropriate.
[COMPANY_001] Confidential Page 51
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
8.4.[ADDRESS_544330] pregnancy  testing. See the 
Assessment schedule, Table 8-1, for timing of the protocol required pregnancy  testing; 
additional pregnancy  testing may be performed to meet local requirements*. A positive urine 
pregnancy  test requires immediate 
interruption of study  treatment until serum beta-human 
chorionic gonadotropin β -hCG is performed and found to be negative. 
*If additional pregnancy  testing is needed per local requirements, those additional results will 
be kept as source documentation only . 
8.4.6 Other safety  evaluations
[IP_ADDRESS] Best -Corrected Visual A cuity (BCV A)
ETDRS BCVA will be obtained in each eye separatel y. This assessment is to be performed 
prior to pupil dilation. The number of letters read correc tly (for each eye) will be recorded in 
the appropriate eCRF page.
[IP_ADDRESS] Intraocular Pressure (IOP)
Intraocular pressures will be measured per the study site’s regular practice.
[IP_ADDRESS] Fluorescein angiography (FA )
FA using a standardized technique (with transit views ofthe study  eye) will be performed on 
the designated eye(s) for each patient according to the Assessment schedule (Table 8-1)and the 
imaging manual.
[IP_ADDRESS] Slit lamp biomicroscopy
Slit lamp exam of the adnexae, conjunctiva/sclera, cornea, anterior chamber, iris, and lens will 
be obtained on both ey e(s) for each patient according to the Assessment Schedule ( Table 8-1). 
Results from the slit lamp biomicroscopy  exam for both eyes will be recorded in the appropriate 
eCRF page.
[IP_ADDRESS] Dilated fundus exam
Dilated exam of the vitreous, optic nerve, choroid, macula, peripheral retina will be obtained 
on the designated eye(s) for each patient according to the Assessment schedule (Table 8-1). 
Theprocess will be outlined in the SOM. 
[IP_ADDRESS].1 Vitreous haze and hemorrhage
During the above examination, additional attention should be directed to scoring the evaluation 
for retinal tear/detachment, retinal hemorrhage, vitreous hemorrhage, density and vitreous haze. 
Results from the dilated fundus exam (for each eye) will be recorded on the appropriate eCRF 
page. Vitreous Haze grade will be outlined in the SOM.
[COMPANY_001] Confidential Page 52
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
[IP_ADDRESS] Spectral -Domain Optical coherence tomography  (SD-OCT)
SD-OCT will be performed on the designated eye(s) for each patient according to the 
Assessment Schedule (Table 8-1) and the imaging manual provided by [CONTACT_430344] (CRC). SD-OCT images will be tra nsferred to theCRC. Certification of the equipment 
and examiners at each investigative site will occur prior to evaluation of study  patients.
[IP_ADDRESS] Color Fundus Photo
Color fundus photography  will be performed on the designated eye(s) for each patient accordin g 
to 
theAssessment schedule (Table 8-1)and the imaging manual. Fundus photograph will be 
performed according to a standardized procedure for the collection of fundus photographic 
images as outlined in a separate manual provided by [CONTACT_10186]. Training of examiners at each 
investigative site will occur prior to evaluation of study  patients.
Commercially Confidential Information
[COMPANY_001] Confidential Page 53
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
8.5 Additional assessments
8.5.1 Pharmacokinetics , 
Quantitation of total LKA651, free ranibizumab,
 will be performed. 
For a detailed PK ,  sampling schedule, please refer to the Assessment 
schedule (Table 8-1), SOM, and the lab manual. All samples will be given a unique sample 
number and a collection number as outlined in the SOM. Additional collection, processing and 
shippi[INVESTIGATOR_430325]651 and 
ranibizumab are available in the SOM.  Additional collection, processing and shippi[INVESTIGATOR_430326] -LKA651 antibodies and anti -ranibizumab antibodies 
are available in the SOM.
Commercially Confidential Information
CCI
CCICommercially Confidential Information
[COMPANY_001] Confidential Page 54
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
8.5.[ADDRESS_544331] be discontinued under the following circumstances:
An SAE or severe AE that in the opi[INVESTIGATOR_430327].
Patient/guardian decision - patient s may  choose to discontinue study  treatment for an y
reason at an y time.
The investigator believes that continuation would negativel y impact the safety of the
patient or the risk/bene fit ratio of trial participation.
Any protocol deviation that results in a significant risk to the 
patient ’s safety .
Pregnancy  (see Section 8.4 (Safet y) and Section 10.1.4 (Pregnancy  reportin g))
Use of prohibited treatment as outlined in Table 6 -3.
Any laboratory  abnormalities that in the judgment of the investigator, taking into
consideration the 
patient ’s overall status, prevents the patient from continuing
participation in the study .
Emergence of the following adverse events:
Acute, marked, reduction in visual acuity, defined as either of the following: At least
a 3-line (15- letter) decrease within the first [ADDRESS_544332]
a 5-line (25
-letter) decrease as assessed on any  post injection day  through Day  15.
Presence of persistent grade 2 or more anterior chamber inflammation (cells ± flare)
for 14 day s or more following IVT injection of study  drug.
An increase i n vitreous inflammation of 2 units on a Vitreous Haze Scale sustained
over 14 day s or more following IVT injection of study  drug.
Commercially Confidential Information
[COMPANY_001] Confidential Page 55
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Sustained elevation of intraocular pressure characterized by [CONTACT_139648] 15 mmHg 
over pre -dose value for >60 minutes, or an intraocular pressure >30 mmHg 
maintained for an hour after the injection.
The following deviations from the protocol treatment: 
Treatment with LKA651 and/or Lucentis®within less than [ADDRESS_544333] determine the primary  reason for 
the patient ’s premature discontinuation of study  treatment and record this information on the 
Dosage Administration CRF.
Patient s who discontinue study  treatment or who decide they do not wish to participa te in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see Section 9.1.2, Withdraw of I nformed Consent). Where possible, they  should 
return for the assessments indicate d by [CONTACT_61140] (*) in the Assessment table . Ifthey fail to 
return for these assessments for unknown reasons, every  effort (e.g. telephone, e-mail, letter) 
should be made to contact [CONTACT_4677] /pre-designated contact [CONTACT_335301] 9.1.3
(Lostto follow -up). This contact [CONTACT_37283] y be done according to the study  visit schedule.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
new / concomitant treatments
adverse events/Serious Adverse Events
The investigator must also contact [CONTACT_430346] ’s discontinuation from study  
treatment .
[IP_ADDRESS] Replacem ent policy
Not applicable .
9.1.[ADDRESS_544334]:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
[COMPANY_001] Confidential Page 56
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Further attempts to contact [CONTACT_430347] y findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
Assessment table . 
[COMPANY_001] will continue to keep and use collected study information (including any data resulting from 
the analy sis of a subject’s samples until their time of withdrawal) according to applicable law.
For US and Japan: All biological sa mplesnot y et anal yzed at the time of withdrawal maystill 
be used for further testing/analy sis in accordance with the terms of this protocol and of the 
informed consent form.
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by  [CONTACT_1289]. They will be stored according to applicable 
legal requirements.
Further attempts to contact [CONTACT_18618] -up.
Allefforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient ’s study  withdrawal should be made as detailed in the 
Assessment table .
[COMPANY_001] will continue to retain and use all research results (data) that have alread y been 
collected for the study  evaluation.
9.1.[ADDRESS_544335] show "due diligence" by 
[CONTACT_268295] , e.g. dates of telephone 
calls, registered letters, etc. A patient should not be considered as lost to follow -up until due 
diligence has been completed .
9.1.4 Study stoppi[INVESTIGATOR_430328] y part of 
the study :
One (1) or more patients presenting with acute or delay ed hypersensitivity  of study  drug 
administr ation.
One (1) or more patients presenting wit h a serious adverse event (SAE)
that, in the 
opi[INVESTIGATOR_871], is related to the stud y drug, at an y time during the trial.
Patient(s) presenting with dose -limiting toxicity defined as any  one of the following 
suspected to be related to study  drug administration: 
Two (2) or more patients presenting with:  
Acute, marked, reduction in visual acuity, defined as either of the following:
Atleast a 3- line (15 -letter) decrease within the first 8 day s that persists until 
[COMPANY_001] Confidential Page 57
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
day15, or at least a 5- line (25- letter) decrease as assessed on any  post injection day  
through Day  15.
Presence of persistent grade 2 anterior chamber infl ammation (cells ± flare) for 
14days or more following IVT injection of study  drug.
An increase in vitreous inflammation of 2 units on a Vitreous Haze Scale for 
14days or more following IVT injection of study  drug.
Sustained elevation of intraocular pressure cha racterized by  [CONTACT_139648] 
15mmHg over pre -dose value for >60 minutes, or an intraocular 
pressure >30 mmHg maintained for an hour after the injection.
The aggregate severit y, frequency, and/or drug relatedness of adverse events, in the 
opi[INVESTIGATOR_871], merit placing the study  on hold; or
Other clinicall y significant changes or effects that, in the opi[INVESTIGATOR_2515], are deemed unsafe to continue dosing
The study  may  resume following the safet y review, if the Investigator sand Sponsor agree it is 
safe to proceed.
9.1.5 Early  study termination by  [CONTACT_430348]. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
[COMPANY_001] will alway s consider the patient welfare and safet y. Should early  termination be 
necessary , patient s must be seen as soon as possible (provide instruction for contact[CONTACT_348194] , when the patient should stop taking drug, when the patient should come for a final visit) 
and treated as a prematurely  withdrawn patient. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the patient ’s interests. The investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.
9.[ADDRESS_544336] -study  treatment
Each patient will be required to complete the study  in its entirety  and thereafter no further study  
treatment will be made available to them. There are approved medications for the disease under 
study , and the patient can continue treatment with these medications as per his or her physician’s 
recommendation.
Study  completion is defined as when the last patient completes their Study Completion visit, 
and any repeat assessments associated with this visit have been documented and followed- up 
appropriatel y by [CONTACT_737], or in the event of an early  study termination decision, the date 
of that decision.
[COMPANY_001] Confidential Page 58
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events (AEs)
An AE is any untoward medical occurrence (e.g., any unfavorable and unintended sign 
[including abnormal laboratory  findings], symptom or disease) in a patient or clinical 
investigation patient after providing written informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual patient and 
identify ing adverse events.
Nova rtis qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of AE s must be sought b y non -directive questioning of the patient at each visit 
during the study . AEs also may  be detected w hen they  are volunteered by  [CONTACT_430349], laboratory  test findings, or other 
assessments.
AEs must be recorded in the A ECRF under the signs, sy mptoms or diagnosis associated with 
them, accom panied by [CONTACT_6644] (as far as possible) (if the event is serio us 
refer to Section 10.1.2):
1.The severit y grade
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.
Its relationship to the study  treatment If the event is due to lack of efficacy  or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causalit y 
will usually  be ‘Not suspected’. The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  orprogression of underly ing illness are not caused by  [CONTACT_6645], they  
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by [CONTACT_49430], not on a 
single patient
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4. W hether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5. A ction taken regarding with study  treatment.
All AEs must be treated appropriately. Treatment may include one or more of the following:
Dose not changed
Dose Reduced/increased
[COMPANY_001] Confidential Page 59
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Drug interrupted/withdrawn
6.its outc ome  
a.not recovered/not resolved;
b.recovered/resolved;
c.recovering/resolving,
d.recovered/resolved with sequelae; 
e.fatal; or unknown
Information about adverse drug reactions for the investigational drug can be found in the IB.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to b e non -typi[INVESTIGATOR_286813] s with 
the underl ying disease.
Follow the instructions found in the SOMfor data capture methodology  regarding AE collection 
for patient s that fail screening.
10.1.2 Serious adverse events (SAEs)
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the patien twas at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in co ndition 
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_5316]’s 
general condition
[COMPANY_001] Confidential Page 60
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. defined as an event that jeopardizes the patie ntor may  require 
medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_18534]. Such events should be 
considered as “medicall y significa nt”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_37209].
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met .
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred. 
10.1.[ADDRESS_544337] be reported separatel y as a new event.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment, a [COMPANY_001] Chief Medical 
Office and Patient Safety  (CMO & PS) Department associate may urgently  require further 
information from the investigator for health authority  reporting. [COMPANY_001] may  need to issue an 
Investigator Notification (IN) to inform all investigators involved in any study  with the same 
study  treatmen t that this SAE has been reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the 30 day  period should only  be reported to [COMPANY_001] Safety if the 
investigator suspects a causal relationship to study treatment.
[COMPANY_001] Confidential Page 61
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
10.1.[ADDRESS_544338] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_430350]&PS. 
Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the investigational study  treatment any pregnancy  outcome. 
Any SAE experienced during pregnancy  must be reported.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, patient or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study treatment errors and uses outside of what is f oreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safety database irrespective of it being associated with an AE/SAE 
within 24 hours of I nvestigator’s awareness. Please see Table 10 -1for details.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error typeDocument in Dose 
Administration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E 
form
Unintentional study 
treatment errorYesOnly if associated 
with an AEOnly if associated 
with an SAE
Misuse/Abuse Yes YesYes, even if not 
associated with a 
SAE
For more information on AE and SAE definition and reporti ng requirements, please see the
respective sections.
[COMPANY_001] Confidential Page 62
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
10.[ADDRESS_544339] been trained. Automati c validation programs check for data discrepancies in the 
eCRFs, allow modification and/or verification of the entered data by  [CONTACT_6649].
The investigator/designee is responsible for assuring that the data (recorded on CRFs) 
(entered into eCRF ) is complete, accurate, and that entry and updates are performed in a timel y 
manner. The Investigator must certify that the data entered are complete and accurate
After final database lock, the investigator will receive copi[INVESTIGATOR_430329].
Automatic validation programs check for data discrepancies and, by [CONTACT_221997], allow the data to be confirmed or corrected before transfer of the data to the 
vendor working on behalf of [COMPANY_001] .
Remote monitoring of the original electronic source records 
will take place, however on-site 
monitoring inspections will continue to take place in order to review data entry  of source 
documentation directly  captured on paper and transcribed into the system, to ensure protocol 
adherence, to assess site operational capabilities, and to perform other monitoring activities that 
cannot be performed remotely .
The investigator must certify  that the data entered into eCRF are complete and accurate. 
After database lock, the investigator will receive copi[INVESTIGATOR_105196].
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
11.2 Database management and qualit y control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepa ncies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
[COMPANY_001] Confidential Page 63
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for re gulatory  activities (MedDRA) terminology .
Randomization codes and data about all study  treatment (s) dispensed to the patient and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to [COMPANY_001] at specific timelines.
Each occurrence of a code break via IRT will be reported to the clinical team and monitor. 
Thecode break functionality  will remain available until study shut down or upon request of 
[COMPANY_001].
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and the treatment codes will be unmasked and made 
available for data analysis/moved to restricted area to be accessed by [CONTACT_6651] .Any changes to the database after that time can only be made after written 
agreement by  [CONTACT_188660].
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a 
[COMPANY_001] /delegated CRO representative will review the protocol and data capture requirements 
(i.e. eSource DDE or eCRFs) with the investigators and their staff. During the study , [COMPANY_001]
employ s several methods of ensuring protocol and GCP compliance and the quality /integrity  of 
the sites’ data. The field monitor will visit the site to check the completeness of patient records, 
the accuracy  of data capture / data entry , the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study  treatment is being stored, 
dispensed, and accounted for according to specifications. Keystudy  personnel must be available 
to assist the field monitor during these visits. Continuous remote monitoring of each site’s data 
may be performed by a centralized [COMPANY_001]/ delegated CRO /CRA organization. 
Additionally , a central analy tics organization may analy ze data & identify  risks & trends for 
site operational parameters, and provide reports to [COMPANY_001] clinical teams to assist with trial 
oversight.
Commercially Confidential Information
[COMPANY_001] Confidential Page 64
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on eCRFs must be traceable to these source documents inthe 
patient ’s file. The investigator must also keep the original informed consent form signed b y the 
patient (a signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. 
Additional checks of the consistency  of the source data with the eCRFs are performed according 
to the study -
specific monitoring plan. No information in source documents about the identity 
of the patient s will be disclosed.
[ADDRESS_544340] quartile, minimum and 
maximum.
12.1 Analysis sets
For all analy sis sets, patients will be anal yzed according to the study  treatment(s) received.
The safet y analysis set will include all 
patients that received an y stud y drug.
The PD and efficacy  analysis set will include all patient s with available PD and efficacy  data 
and no protocol deviations with relevant impact on PD or efficacy  data.
12.2 Patient demographics and other baseline characteristics
All data for backgr ound and demographic variables will be listed by [CONTACT_90217] . 
Summary  statistics will be provided by  [CONTACT_1570].
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be listed b y treatment group and patient .
12.3 Treatments
Data for stud y drug administration and concomitant therapi[INVESTIGATOR_430330] .
[COMPANY_001] Confidential Page 65
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
12.4 Analysis of the primary  endpoint(s)
12.4.1 Definition of primary  endpoint(s)
Primary  efficacy  endpoints for this study  are BCVA as assessed by [CONTACT_430351] y charts 
at week [ADDRESS_544341] at week 12. Primary safet y 
endpoints include adverse events, vital signs, ECG intervals, safety  laboratory  measures, and 
complete ophtha lmic exam, including: intraocular pressure, BCVA, dilated fundus exam , slit 
lamp examination, macular thickness b y SD-OCT, and FA.
12.4.[ADDRESS_544342]-square means for each treatment by [CONTACT_430352]. Additionally  at each time, the difference between the 
combination treatment and Lucentis®alone, as well as the difference between LKA651 and 
Lucentis®alone will be prese nted along with the resulting p-value and 90% confidence interval. 
The primary  inference will be based on the null hypothesis on no treatment difference for Day 
85.
A one -sided, alpha=0.[ADDRESS_544343]. Thus, analy sis will also be done with untransformed 
data, but with deference given to the inferential results (p-values and confidence intervals) of 
the log- transformed analy sis.
Safety  anal ysis isdescribed in Section 12.5.1.
12.4.3 Handling of missing values/censoring/discontinuations
Missing values will be accounted for m y using mixed methods repeated measures.
12.4.4 Sensitivity and Supportive analy ses
Commercially Confidential Information
[COMPANY_001] Confidential Page 66
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
12.5 Analysis of secondary  endpoints
Time to retreatment with anti-VEGF (as determined by [CONTACT_976]) after week 12 may be examined 
with a Kaplan -Meier plot; however, this may be abandoned if the time data are too sparse for 
accurate model fitting. 
12.5.1 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_430353] (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate summary  for death including on treatment and post 
treatment deaths will be provided. In particular, summary  tables for AEs will summarize only 
on-treatment events, with a start date during the on -treatment period (treatment -emergent AEs).
The on -treatment period lasts from the date of first administration of study  treatment to the end 
of the extension phase. 
Adverse events
All information obtained on adverse events will be display ed by [CONTACT_90217] .
The number (and percentage) of patient s with treatment emergent adver se events (events started 
after the first dose of study medication or events present prior to start of double -blind treatment 
but increased in severit y based on preferred term) will be summarized in the following way s:
by [CONTACT_3148], primary  system organ cl ass and preferred term.
by [CONTACT_3148], primary  system organ class, preferred term and maximum severity .
by [CONTACT_3148], Standardized MedDRA Query  (SMQ) and preferred term
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events, other significant adverse events leading to discontinuation and adverse events 
leading to dose adjustment .
A patient with multiple AEs within a primary  system organ class is only  counted once towards 
the total of the primary  system organ class.
Vital signs
All vital signs data will be listed by [CONTACT_3148], patient, and visit/time and if ranges are available 
abnormalities (and relevant orthostatic changes) will be flagged. Summary  statistics will be 
provided b y treatment and visit/time .
Commercially Confidential Information
[COMPANY_001] Confidential Page 67
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
12-lead ECG
All ECG data will be listed by  [CONTACT_3148], patient and visit/time, abnormalities will be flagged. 
Summary  statistics will be provided by  [CONTACT_10659]/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_3148], patient, and visit/time and if normal ranges are 
available abnormalities will be flagged. Summary  statistics will be provided by [CONTACT_103913]/time.
12.5.[ADDRESS_544344] dose, if feasible, using non-compartmental 
method(s): area under the curve AUC last, AUC 0
-28d, Maximal concentration (Cmax), and time to 
the first occurrence of the maximal concentration (Tmax). PK parameters will be determined 
using non-compartmental methods using the most recent version ofWinNonlin Phoenix 
(Version 8.2).
Descriptive summaries including mean, coefficient of vari
ation, median, minimum and 
maximum  be presented by 
[CONTACT_430354] y day/sampling point.
The derivation of PK parameters at the patient level will be based on observed concentrations 
only,
. A plot of mean concentration- time profile will beconstructed. Plots of 
mean -time concentration profile of total LKA651 concentrations and ranibizumab will also be 
constructed.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 68
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
12.5.5 Patient reported outcomes
Not applicable .
12.6 Analysis of exploratory  endpoints
12.7 Interim analy ses
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 69
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
12.8 Sample size calculation
Twenty  five patients per arm provide 80% power to detect a 5 letter improvement in BCVA 
compared to Lucentis®, p=0.05 (one-sided) for the single comparison (after 12 weeks of 
treatment) , assuming a standard deviation (SD) of 7 letters, the SD observed in the Lucentis®DME 
trials. The software nQuery 7.0 was used to evaluate the power estimation and the sample size .
[COMPANY_001] Confidential Page 70
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Respon sibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, patient recruitment procedures 
(e.g., advertisements) and any other written information to be provided to patient s. Prior to 
study  start, the investigator is required to sign a protocol signature [CONTACT_5389]/her 
agreement to conduct the study  in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
[COMPANY_001] monitors, auditors, [COMPANY_001] Qualit y Assurance representatives , designated agents of 
[COMPANY_001], IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site 
is requested by a regulatory  authorit y, the investigator must inform [COMPANY_001] immediately  that 
this request has been made.
13.[ADDRESS_544345]. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study r eport the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the [COMPANY_001] clinical trial results 
website and all required Health Authority  websites (e.g. Clinicaltrials.go v, EudraCT etc.) .
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings
13.[ADDRESS_544346] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP reg ulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process us es a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes .
[COMPANY_001] Confidential Page 71
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
[ADDRESS_544347] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_18686] B/IEC and health authorities, where required, it cannot be implemented.
14.[ADDRESS_544348] be approved by [CONTACT_5343], health autho
rities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for patient safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safet y of any patient included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.
[COMPANY_001] Confidential Page 72
Amended Protocol Version v0 6 (Clean ) Protocol No. CLKA651X2202
[ADDRESS_544349]
DRCRnet (2007) Relationship between optical coherence tomograph y-measured central 
retinal thickness and visual acuit y in diabetic macular edem a. Ophthalmology ;114(3):525 -
536
ETDRS (1985) Photocoagulation for Diabetic Macular Edema - Early  Treatment Diabetic -
Retinopathy  Study  Report,  Archives of Ophthalmology ; 103:1796-1806.
Jaffe
GJ, Eliott D, Wells JA, et al (2016) A Phase 1 Study  of Intravitreous E [ZIP_CODE] in 
Combination with Ranibizumab in 
Neovascu lar Age -Related Macular Degeneration. 
Ophthalmology ;123(1):78 -85.
Klein R, Klein BEK, Moss SE, et al (1995) The Wisconsin Epi[INVESTIGATOR_50123] -Study  of Diabetic -
Retinopathy  the L ong-Term Incidence of Macular Edema. Ophthalmology ;102:
7-16.
Lin CS, L im SK, D’Agati V, et al (1996). Differential effects of an ery thropoietin receptor 
gene dis -ruption on primitive and definitive ery thropoiesis. Genes Dev ;10:154 -164.
Lira RP, Oliveira CL , Marques MV, et al (2007) Adverse reactions of fluorescein 
angiograph y: a prospective study . Arq Bras Oftalmol ; 70(4): 615-618 .
Mitchell P, Bandello F, Schmidt -Erfurth U, et al (2011) The RESTORE study : ranibizumab 
monotherap y or combined with laser versus laser monotherap y for diabetic macular edema. 
Ophthalmology ;
118:615-625.
Mones J(2010) Complement Factor 5 Inhibition in Age -related Macular Dege neration. Retina 
Today . October 2010: 52-55
Wrob lewski JJ, Hu AY (2016) Topi[INVESTIGATOR_430331] 0.2% and Intravitreal Ranibizumab 0.5 
mg as Combination Therapy  for Macular Edema Due to Branch and Central Retinal Vein 
Occlusion: An Ope n-Label, Randomized Study . OSLIRetina ;47(10):914 -923.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information